Abstract
This study investigates the effects of Poloxamer 188 (P188) on neutrophil chemotaxis following burn injury in male and female mice using a microfluidic system. Utilizing male and female CD1 mice, we evaluated neutrophil migration towards two chemoattractants, N-formyl-l-methionyl-l-leucyl-l-phenylalanine (fMLP) and Leukotriene B4 (LTB4), and FPR1 and BLT1 G protein-coupled receptors after administering P188. Our findings revealed that P188 significantly increased the migration toward LTB4 in both sexes. Additionally, our findings highlight the upregulation of BLT1 and FPR1 markers due to burn injury in both female and male mice in the Burn vs. Sham groups. These results demonstrate the potential of P188 in modulating neutrophil behavior post-burn injury in therapeutic strategies for inflammation management. This microfluidic platform offers a precise and controlled microenvironment for studying neutrophil chemotaxis post-burn injury with and without P188 treatment.
Introduction
Severe burn injuries trigger massive systemic inflammation. Neutrophils, the primary immune responders, migrate to injury sites to clear debris and combat pathogens. However, dysfunctional chemotaxis—uncontrolled or hyperactive migration—can lead to secondary organ damage. Poloxamer 188 (P188), an FDA-approved synthetic copolymer, is known to stabilize damaged cell membranes and reduce inflammation. This study investigates how P188 modulates neutrophil chemotaxis post-burn, particularly focusing on sex-specific responses, which are often overlooked despite clinical evidence of higher mortality risks in female burn patients.
Methods
The study utilized a murine burn model (30-40% total body surface area) and a custom microfluidic platform to observe dynamic immune cell behavior. Neutrophils from male and female CD1 mice were evaluated under two treatment conditions: systemic (IV injection of P188) and ex vivo (direct treatment of isolated cells).
The microfluidic device, fabricated from PDMS, featured a central loading chamber flanked by chemoattractant reservoirs containing fMLP (a bacterial signal) and LTB4 (a pro-inflammatory lipid). This dual-gradient setup allowed researchers to observe competitive migration. Single-cell tracking was performed using time-lapse microscopy and a custom MATLAB script utilizing Laplacian of Gaussian (LoG) filters to quantify specific migratory phenotypes.
Key Insights
- Signal Preference Shift: P188 treatment caused neutrophils to prioritize LTB4 (tissue inflammation) over fMLP (bacterial signals), suggesting a shift toward resolving local tissue damage.
- Sex-Specific Responses: Female mice exhibited a significantly stronger migratory response to P188 compared to males, highlighting the importance of biological sex in immunomodulatory therapy design.
- Systemic Interaction: The difference between systemic and ex vivo treatment effects indicates that P188 interacts with systemic factors in the bloodstream to modulate cell directionality.
- Molecular Mechanism: While burn injury upregulates FPR1 and BLT1 receptors, P188 does not alter their expression levels, implying it modulates migration through an alternative molecular pathway.
Results
The study quantified several migratory phenotypes to assess the impact of P188:
- Migration Percentage: Systemic P188 significantly boosted migration toward LTB4. In females, migration increased from 6.6% (burn) to 22.87% (burn + P188). In males, it rose from 10.6% to 17.96%.
- Velocity Normalization: Burn injury induced hyperactivity in neutrophils. Female neutrophil velocity increased from ~6.05 µm/min (sham) to 9.56 µm/min (burn). Systemic P188 restored this to 6.73 µm/min, closer to baseline.
- Receptor Expression: Burn injury significantly increased gene expression of FPR1 and BLT1 in both sexes. P188 treatment did not significantly alter these elevated levels.
Discussion and Future Directions
The findings demonstrate P188's potential as a sex-aware immunomodulatory therapy for managing post-burn inflammation. However, the exact molecular mechanism by which P188 alters chemotaxis remains to be elucidated, as it does not directly affect receptor expression. Future research should explore 3D human tissue models and vascularization to better translate these findings to clinical settings. Additionally, investigating P188's effects on other immune cell types will be critical for developing comprehensive therapeutic strategies for systemic inflammation.
Summary updated